When basal insulin therapy in type 2 diabetes mellitus is not enough--what next?
about
Intensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapyTreatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsEfficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled TrialInitiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond.Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus.Insulin Therapy: A Personal ApproachEvaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trialsClinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE.Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practiceStepwise intensification of insulin therapy in type 2 diabetes management--exploring the concept of the basal-plus approach in clinical practice.Jiang Tang Xiao Ke Granule, a Classic Chinese Herbal Formula, Improves the Effect of Metformin on Lipid and Glucose Metabolism in Diabetic Mice.Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study.Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus.Self-mixed/split insulin regimen: a serious omission in the ADA/EASD position statementHow do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatmentIntensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom?A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin.Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapyBasal Insulin Use With GLP-1 Receptor Agonists.Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus.Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections.Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017.Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets.Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017A higher blood glucose level pre-breakfast in comparison to bedtime is a contraindication for intensification of prandial insulin therapy in patients with type 2 diabetes - The impact of a negative BeAM value
P2860
Q27001931-FF61ECFE-0F10-4ED2-90D0-465E0768D730Q28077026-1A21206B-E86D-4166-B171-FA66D32393FEQ28597145-77D7DC83-F1AE-4040-A47C-3A938E4DBB63Q33610830-8FE522EC-F8A6-4954-BFA2-DD0F027E5749Q35671873-0843DC6F-74A6-4F80-B263-109E51FAC73AQ35856357-5B1EB866-4F75-4843-A12C-277D82F8A553Q36303980-CF5E3606-BE1F-4F63-B99C-4906CEEDFEA1Q36428057-9F028C9F-0CDA-4647-85CE-6A75D68FA69FQ36432159-B4739DC8-A21F-46BC-8EDA-96A75706878DQ36670318-AC8DC15B-7586-4DF9-98A3-A45BFCB50C40Q37063273-2F43A9C1-E9F2-404E-93D2-8B842FB5A379Q37087031-1EA9FBEF-4710-48FC-89CA-BAB01EA7CAD3Q37106467-D58DDDCD-3412-4D54-8F86-A4CC208C2B2FQ37106537-52669278-FD13-422B-9295-733EA41122D4Q37107135-04E73CCB-6393-49C4-9B51-478B1E80E0A0Q37199330-B6EC384B-E5BA-43F1-94EA-D55A3E2A2538Q37403216-A0091F1B-675E-4293-B74E-4F537D55B587Q37577129-D77E3A32-28A2-41E9-AD84-EC2BFBF1A6B9Q37577153-C2E61AA6-D96F-46E1-97A0-A4CCBB62FDF0Q37696539-1EEA1282-A2AF-46BE-AD0E-2173F0A3B595Q38154623-6755E170-27D0-4683-B30D-D094EC8E9584Q38692092-5776C1B2-48DF-4927-88DF-F944D79D434DQ38940711-6497AB2F-85D4-47D6-A6C4-0489DBA1A7A3Q39345916-C5A985CD-38F0-4B77-9DD0-144509CDC13AQ40955003-5AAC0C7D-FF93-4A24-8DBD-50F228F00887Q42703474-6849F521-E56B-48A4-AB2F-862AFDAAFF39Q42703652-4DAE31D3-7C11-490F-ADBF-8AC0FA7C2929Q46094723-82118505-DA7E-4DD4-B7D4-F9F405180488Q47142499-4CFE0B78-C637-4B51-8276-6FB14166F3A4Q50271509-E02E3783-6C7E-41C5-AE19-290E8DDAC49BQ57217641-3831D735-1076-467C-AA69-246089A4F728Q58713815-52D55236-FB68-43D0-AFF2-3A923D83367D
P2860
When basal insulin therapy in type 2 diabetes mellitus is not enough--what next?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
When basal insulin therapy in type 2 diabetes mellitus is not enough--what next?
@ast
When basal insulin therapy in type 2 diabetes mellitus is not enough--what next?
@en
type
label
When basal insulin therapy in type 2 diabetes mellitus is not enough--what next?
@ast
When basal insulin therapy in type 2 diabetes mellitus is not enough--what next?
@en
prefLabel
When basal insulin therapy in type 2 diabetes mellitus is not enough--what next?
@ast
When basal insulin therapy in type 2 diabetes mellitus is not enough--what next?
@en
P2093
P356
P1476
When basal insulin therapy in type 2 diabetes mellitus is not enough--what next?
@en
P2093
David Owens
Denis Raccah
Matthew Riddle
Reinhard G Bretzel
P2860
P304
P356
10.1002/DMRR.733
P577
2007-05-01T00:00:00Z